Search

The World Health Organization estimated that in the year 2017, there were 219 million cases of malaria in 90 countries across the world. Over 99%of these cases were caused from Plasmodium falciparum in the WHO African region and WHO regions of South-East Asia. Nearly half a million deaths occurred in the year 2017 from malaria across the world. The current treatment involves a combination therapy of an artemisinin derivative and a second medication such a chloroquine. Resistance is being noted in these regions with heavy medication use, and the need for developing a new method of treatment is becoming ever more critical. In our laboratory we have shown that N-Methylfluoxetine has activity against the parasite Plasmodium falciparum. Expanding on this discovery, our laboratory group has synthesized a small set of N-Methylfluoxetine derivatives with substitution of the trifluoro methyl group. We have also started a new series of drug testing with diphenylpropylamines, testing these derivatives against Plasmodium falciparum using SYBER Green Assay. [ABSTRACT FROM AUTHOR]